Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Nov 1;98(9):2109–2119. doi: 10.1172/JCI119017

Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression.

J J Letterio 1, A G Geiser 1, A B Kulkarni 1, H Dang 1, L Kong 1, T Nakabayashi 1, C L Mackall 1, R E Gress 1, A B Roberts 1
PMCID: PMC507656  PMID: 8903331

Abstract

The progressive inflammatory process found in transforming growth factor beta1 (TGF-beta1)-deficient mice is associated with several manifestations of autoimmunity, including circulating antibodies to nuclear antigens, immune complex deposition, and increased expression of both class I and class II major histocompatibility complex (MHC) antigens. The contribution of MHC class II antigens to the genesis of this phenotype has been determined by crossing the TGF-beta1-null [TGF-beta1(-/-)] genotype into the MHC class II-deficient [MHC-II(-/-)] background. Mice homozygous for both the TGF-beta1 null allele and the class II null allele [TGF-beta1(-/-);MHC-II(-/-)] are without evidence of inflammatory infiltrates, circulating autoantibodies, or glomerular immune complex deposits. Instead, these animals exhibit extensive extramedullary hematopoiesis with progressive splenomegaly and adenopathy, surviving only slightly longer than TGF-beta1(-/-);MHC-II(+/+) mice. The role of CD4+ T cells, which are also absent in MHC class II-deficient mice, is directly demonstrated through the administration of anti-CD4 monoclonal antibodies in class II-positive, TGF-beta1(-/-) mice. The observed reduction in inflammation and improved survival emphasize the significance of CD4+ cells in the pathogenesis of the autoimmune process and suggest that the additional absence of class II antigens in TGF-beta1(-/-);MHC-II(-/-) mice may contribute to their extreme myeloid metaplasia. Thus, MHC class II antigens are essential for the expression of autoimmunity in TGF-beta1-deficient mice, and normally may cooperate with TGF-beta1 to regulate hematopoiesis.

Full Text

The Full Text of this article is available as a PDF (11.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boivin G. P., O'Toole B. A., Orsmby I. E., Diebold R. J., Eis M. J., Doetschman T., Kier A. B. Onset and progression of pathological lesions in transforming growth factor-beta 1-deficient mice. Am J Pathol. 1995 Jan;146(1):276–288. [PMC free article] [PubMed] [Google Scholar]
  2. Bombara C., Ignotz R. A. TGF-beta inhibits proliferation of and promotes differentiation of human promonocytic leukemia cells. J Cell Physiol. 1992 Oct;153(1):30–37. doi: 10.1002/jcp.1041530106. [DOI] [PubMed] [Google Scholar]
  3. Brandes M. E., Allen J. B., Ogawa Y., Wahl S. M. Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest. 1991 Mar;87(3):1108–1113. doi: 10.1172/JCI115073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carlino J. A., Higley H. R., Creson J. R., Avis P. D., Ogawa Y., Ellingsworth L. R. Transforming growth factor beta 1 systemically modulates granuloid, erythroid, lymphoid, and thrombocytic cells in mice. Exp Hematol. 1992 Sep;20(8):943–950. [PubMed] [Google Scholar]
  5. Christ M., McCartney-Francis N. L., Kulkarni A. B., Ward J. M., Mizel D. E., Mackall C. L., Gress R. E., Hines K. L., Tian H., Karlsson S. Immune dysregulation in TGF-beta 1-deficient mice. J Immunol. 1994 Sep 1;153(5):1936–1946. [PubMed] [Google Scholar]
  6. Dang H., Geiser A. G., Letterio J. J., Nakabayashi T., Kong L., Fernandes G., Talal N. SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol. 1995 Sep 15;155(6):3205–3212. [PubMed] [Google Scholar]
  7. Deeg H. J., Beckham C., Huss R., Myerson D., Greinix H., Appelbaum F. R., Graham T., Schuening F., Storb R. Rescue from anti-MHC class II antibody-mediated marrow graft failure by c-kit ligand. Blood. 1994 Apr 15;83(8):2352–2359. [PubMed] [Google Scholar]
  8. Dialynas D. P., Quan Z. S., Wall K. A., Pierres A., Quintáns J., Loken M. R., Pierres M., Fitch F. W. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol. 1983 Nov;131(5):2445–2451. [PubMed] [Google Scholar]
  9. Diebold R. J., Eis M. J., Yin M., Ormsby I., Boivin G. P., Darrow B. J., Saffitz J. E., Doetschman T. Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12215–12219. doi: 10.1073/pnas.92.26.12215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Eisenberg R. A., Craven S. Y., Warren R. W., Cohen P. L. Stochastic control of anti-Sm autoantibodies in MRL/Mp-lpr/lpr mice. J Clin Invest. 1987 Sep;80(3):691–697. doi: 10.1172/JCI113123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fontana A., Constam D. B., Frei K., Malipiero U., Pfister H. W. Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Immunol. 1992;99(1):1–7. doi: 10.1159/000236328. [DOI] [PubMed] [Google Scholar]
  12. Gamble J. R., Khew-Goodall Y., Vadas M. A. Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J Immunol. 1993 May 15;150(10):4494–4503. [PubMed] [Google Scholar]
  13. Geiser A. G., Letterio J. J., Kulkarni A. B., Karlsson S., Roberts A. B., Sporn M. B. Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9944–9948. doi: 10.1073/pnas.90.21.9944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Greinix H. T., Storb R., Bartelmez S. H. Specific growth inhibition of primitive hematopoietic progenitor cells mediated through monoclonal antibody binding to major histocompatibility class II molecules. Blood. 1992 Oct 15;80(8):1950–1956. [PubMed] [Google Scholar]
  15. Grusby M. J., Johnson R. S., Papaioannou V. E., Glimcher L. H. Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice. Science. 1991 Sep 20;253(5026):1417–1420. doi: 10.1126/science.1910207. [DOI] [PubMed] [Google Scholar]
  16. Heinrich M. C., Dooley D. C., Keeble W. W. Transforming growth factor beta 1 inhibits expression of the gene products for steel factor and its receptor (c-kit). Blood. 1995 Apr 1;85(7):1769–1780. [PubMed] [Google Scholar]
  17. Hilbert D. M., Shen M. Y., Rapp U. R., Rudikoff S. T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors. Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):649–653. doi: 10.1073/pnas.92.3.649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hines K. L., Kulkarni A. B., McCarthy J. B., Tian H., Ward J. M., Christ M., McCartney-Francis N. L., Furcht L. T., Karlsson S., Wahl S. M. Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor beta 1 knockout mice. Proc Natl Acad Sci U S A. 1994 May 24;91(11):5187–5191. doi: 10.1073/pnas.91.11.5187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jacobsen S. E., Keller J. R., Ruscetti F. W., Kondaiah P., Roberts A. B., Falk L. A. Bidirectional effects of transforming growth factor beta (TGF-beta) on colony-stimulating factor-induced human myelopoiesis in vitro: differential effects of distinct TGF-beta isoforms. Blood. 1991 Nov 1;78(9):2239–2247. [PubMed] [Google Scholar]
  20. Jacobsen S. E., Ruscetti F. W., Roberts A. B., Keller J. R. TGF-beta is a bidirectional modulator of cytokine receptor expression on murine bone marrow cells. Differential effects of TGF-beta 1 and TGF-beta 3. J Immunol. 1993 Nov 1;151(9):4534–4544. [PubMed] [Google Scholar]
  21. Jameson B. A., McDonnell J. M., Marini J. C., Korngold R. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature. 1994 Apr 21;368(6473):744–746. doi: 10.1038/368744a0. [DOI] [PubMed] [Google Scholar]
  22. Khoury S. J., Hancock W. W., Weiner H. L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med. 1992 Nov 1;176(5):1355–1364. doi: 10.1084/jem.176.5.1355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kulkarni A. B., Huh C. G., Becker D., Geiser A., Lyght M., Flanders K. C., Roberts A. B., Sporn M. B., Ward J. M., Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):770–774. doi: 10.1073/pnas.90.2.770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Letterio J. J., Roberts A. B. Transforming growth factor-beta1-deficient mice: identification of isoform-specific activities in vivo. J Leukoc Biol. 1996 Jun;59(6):769–774. doi: 10.1002/jlb.59.6.769. [DOI] [PubMed] [Google Scholar]
  25. Lowrance J. H., O'Sullivan F. X., Caver T. E., Waegell W., Gresham H. D. Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J Exp Med. 1994 Nov 1;180(5):1693–1703. doi: 10.1084/jem.180.5.1693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. McCartney-Francis N. L., Wahl S. M. Transforming growth factor beta: a matter of life and death. J Leukoc Biol. 1994 Mar;55(3):401–409. doi: 10.1002/jlb.55.3.401. [DOI] [PubMed] [Google Scholar]
  27. Miller A., Lider O., Roberts A. B., Sporn M. B., Weiner H. L. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):421–425. doi: 10.1073/pnas.89.1.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pierres A., Naquet P., Van Agthoven A., Bekkhoucha F., Denizot F., Mishal Z., Schmitt-Verhulst A. M., Pierres M. A rat anti-mouse T4 monoclonal antibody (H129.19) inhibits the proliferation of Ia-reactive T cell clones and delineates two phenotypically distinct (T4+, Lyt-2,3-, and T4-, Lyt-2,3+) subsets among anti-Ia cytolytic T cell clones. J Immunol. 1984 Jun;132(6):2775–2782. [PubMed] [Google Scholar]
  29. Racke M. K., Cannella B., Albert P., Sporn M., Raine C. S., McFarlin D. E. Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. Int Immunol. 1992 May;4(5):615–620. doi: 10.1093/intimm/4.5.615. [DOI] [PubMed] [Google Scholar]
  30. Racke M. K., Dhib-Jalbut S., Cannella B., Albert P. S., Raine C. S., McFarlin D. E. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol. 1991 May 1;146(9):3012–3017. [PubMed] [Google Scholar]
  31. Ranges G. E., Sriram S., Cooper S. M. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med. 1985 Sep 1;162(3):1105–1110. doi: 10.1084/jem.162.3.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Reimold A. M., Kara C. J., Rooney J. W., Glimcher L. H. Transforming growth factor beta 1 repression of the HLA-DR alpha gene is mediated by conserved proximal promoter elements. J Immunol. 1993 Oct 15;151(8):4173–4182. [PubMed] [Google Scholar]
  33. Shull M. M., Ormsby I., Kier A. B., Pawlowski S., Diebold R. J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992 Oct 22;359(6397):693–699. doi: 10.1038/359693a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sinha A. A., Lopez M. T., McDevitt H. O. Autoimmune diseases: the failure of self tolerance. Science. 1990 Jun 15;248(4961):1380–1388. doi: 10.1126/science.1972595. [DOI] [PubMed] [Google Scholar]
  35. Sobel R. A., Blanchette B. W., Bhan A. K., Colvin R. B. The immunopathology of experimental allergic encephalomyelitis. II. Endothelial cell Ia increases prior to inflammatory cell infiltration. J Immunol. 1984 May;132(5):2402–2407. [PubMed] [Google Scholar]
  36. Tan E. M. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol. 1982;33:167–240. doi: 10.1016/s0065-2776(08)60836-6. [DOI] [PubMed] [Google Scholar]
  37. Torok-Storb B., Hansen J. A. Modulation of in vitro BFU-E growth by normal Ia-positive T cells is restricted by HLA-DR. Nature. 1982 Jul 29;298(5873):473–474. doi: 10.1038/298473a0. [DOI] [PubMed] [Google Scholar]
  38. Tsunawaki S., Sporn M., Ding A., Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature. 1988 Jul 21;334(6179):260–262. doi: 10.1038/334260a0. [DOI] [PubMed] [Google Scholar]
  39. Vodovotz Y., Bogdan C., Paik J., Xie Q. W., Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med. 1993 Aug 1;178(2):605–613. doi: 10.1084/jem.178.2.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Waegell W. O., Higley H. R., Kincade P. W., Dasch J. R. Growth acceleration and stem cell expansion in Dexter-type cultures by neutralization of TGF-beta. Exp Hematol. 1994 Oct;22(11):1051–1057. [PubMed] [Google Scholar]
  41. Wahl S. M., Allen J. B., Weeks B. S., Wong H. L., Klotman P. E. Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4577–4581. doi: 10.1073/pnas.90.10.4577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Wahl S. M. Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure. J Clin Immunol. 1992 Mar;12(2):61–74. doi: 10.1007/BF00918135. [DOI] [PubMed] [Google Scholar]
  43. Wahl S. M. Transforming growth factor beta: the good, the bad, and the ugly. J Exp Med. 1994 Nov 1;180(5):1587–1590. doi: 10.1084/jem.180.5.1587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wofsy D., Ledbetter J. A., Hendler P. L., Seaman W. E. Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol. 1985 Feb;134(2):852–857. [PubMed] [Google Scholar]
  45. Wofsy D., Seaman W. E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 1;161(2):378–391. doi: 10.1084/jem.161.2.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Yaswen L., Kulkarni A. B., Fredrickson T., Mittleman B., Schiffman R., Payne S., Longenecker G., Mozes E., Karlsson S. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood. 1996 Feb 15;87(4):1439–1445. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES